Autopsy report · NCT06560632

Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors

“Sponsor decided to terminate study early”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 1 month before it stopped.
• 26 participants enrolled.
• Results were posted on the registry 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Repare Therapeutics

Sponsor type

Industry

Conditions

Advanced Solid Tumor

Interventions

RP-3467 at assigned dose and schedule; Olaparib 200-300 mg BID, daily

Participants

26

Sites

5

Countries

United States

Trials that died the same way

• An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
  “The sponsor decided to terminate the study early” (96% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (93% match in meaning)
• Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
  “Sponsor decided to terminate the study” (91% match in meaning)
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
  “Sponsor decision to terminate study.” (90% match in meaning)
• Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
  “Sponsor terminated study” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.